New Delhi: ENTOD Pharmaceuticals, a leading Indian pharmaceutical company, has acquired final approval from the Drug Controller General of India (DCGI) for its novel PresVu eye drops. This marks a significant milestone in the management of presbyopia.
India’s PresVu is the first eye drop designed to reduce the need for reading glasses for presbyopia patients over 40, and the company is seeking a patent for its formulation and technique.
As an added benefit, the patented mixture not only eliminates the need for reading glasses but also helps the patient moisten their eyes. These eye drops feature unique dynamic buffer technology to quickly adapt to tear pH, assuring consistent efficacy and safety for long-term usage, having in mind that such drops will be used for years at a stretch.
Presbyopia, a common aging condition affecting 1.09 billion to 1.80 billion people globally, affects household productivity due to weakening eye focus. Presbyopia is a condition that significantly affects a person’s quality of life, affecting daily tasks and lifestyle. It is often noticed by holding reading materials at arm’s length.
ENTOD Pharmaceuticals’ CEO, Nikkhil K. Masurkar, announced the approval of PresVu, a product developed over years, as part of their mission to transform eye care in India. The DCGI approval signifies ENTOD’s commitment to innovation and providing accessible and affordable healthcare solutions, he added.
Dr. Dhananjay Bakhle praised PresVu’s clinical potential, stating it offers a non-invasive solution for presbyopia patients, enhancing near vision without the need for reading glasses. The rapid efficacy and safety profile of PresVu have been demonstrated in clinical trials.
Dr. Aditya Sethi highlighted the benefits of PresVu, an advanced treatment option for presbyopia, which enhances near vision within 15 minutes. This treatment improves the quality of life for many patients, allowing them to perform everyday tasks with ease. However, it’s crucial to monitor symptoms and seek medical advice if blurry vision interferes with activities.
ENTOD Pharmaceuticals, a leading pharmaceutical company in ENT, ophthalmology, pediatrics, and dermatology, has been a leader in research and development for over 46 years. As PresVu approaches commercial launch, the company is committed to innovation and supporting the ‘Make in India’ initiative.
